Get the Stockscreener App
24.30
1.25%
0.30
Janux Therapeutics Inc stock is traded at $24.30, with a volume of 691.13K.
It is up +1.25% in the last 24 hours and down -7.88% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
See More
Previous Close:
$24.00
Open:
$24.04
24h Volume:
691.13K
Relative Volume:
0.84
Market Cap:
$1.46B
Revenue:
$439.00K
Net Income/Loss:
$-105.64M
P/E Ratio:
-13.50
EPS:
-1.8
Net Cash Flow:
$-60.70M
1W Performance:
-3.23%
1M Performance:
-7.88%
6M Performance:
-32.52%
1Y Performance:
-45.02%
1-Day Range:
$23.89
$25.22
1-Week Range:
$23.30
$26.13
52-Week Range:
$21.97
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
24.30 | 1.53B | 439.00K | -105.64M | -60.70M | -1.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Raymond James | Outperform |
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
AI Tools Suggest Janux Therapeutics Inc. May Outperform This Week2025 Trading Recap & Safe Capital Growth Plans - mustnews.co.kr
Janux Therapeutics Inc. Shows Early Signs of Technical Strength2025 EndofYear Setup & Weekly Hot Stock Watchlists - thegnnews.com
Summit stock gets Neutral view at Piper Sandler (SMMT:NASDAQ) - Seeking Alpha
Janux Therapeutics Receives $10M Milestone Payment from Merck for Advancing Cancer Therapy Collaboration - MSN
Piper Sandler initiates coverage of oncology companies (CGON:NASDAQ) - Seeking Alpha
9 Best Small Cap Stocks with Biggest Upside Potential - Insider Monkey
Is Janux Therapeutics Inc. a candidate for recovery play2025 Earnings Surprises & High Return Stock Watch Alerts - Newser
What moving averages say about Janux Therapeutics Inc.July 2025 Recap & Capital Efficiency Focused Ideas - Newser
Chart based exit strategy for Janux Therapeutics Inc.Dividend Hike & AI Optimized Trading Strategy Guides - Newser
What MACD and RSI say about Janux Therapeutics Inc.Market Trend Summary & Consistent Profit Trade Alerts - Newser
Janux Therapeutics Inc. stock daily chart insights2025 Year in Review & Daily Stock Trend Reports - Newser
Will Janux Therapeutics Inc. continue its uptrend2025 Macro Impact & AI Powered Market Trend Analysis - Newser
Candlestick signals on Janux Therapeutics Inc. stock todayEarnings Risk Report & Expert Approved Trade Ideas - Newser
Chartists Watching For Breakout in Janux Therapeutics Inc.Portfolio Performance Summary & Real-Time Chart Pattern Alerts - metal.it
Live market analysis of Janux Therapeutics Inc.CEO Change & Consistent Profit Trade Alerts - Newser
Why is Janux Therapeutics Inc. stock going upEarnings Trend Report & Expert Approved Trade Ideas - classian.co.kr
Chart overlay techniques for tracking Janux Therapeutics Inc.Quarterly Risk Review & Daily Oversold Bounce Ideas - Newser
How to interpret RSI for Janux Therapeutics Inc. stockPortfolio Update Report & Breakout Confirmation Trade Signals - Newser
Janux Therapeutics Inc. At Critical Juncture — Bounce or BreakdownShort Setup & AI Powered Trade Plan Recommendations - metal.it
Can Janux Therapeutics Inc. disrupt its industryGap Up & High Yield Equity Trading Tips - sundaytimes.kr
Custom strategy builders for tracking Janux Therapeutics Inc.July 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
What makes Janux Therapeutics Inc. stock price move sharplyWeekly Risk Report & Smart Investment Allocation Insights - sundaytimes.kr
Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations - TipRanks
Q3 EPS Forecast for Janux Therapeutics Raised by Analyst - Defense World
Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials - TipRanks
Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $91.89 - Defense World
Janux Therapeutics Inc. Sees Relief Buying After Extended Drop2025 Institutional Moves & Fast Moving Stock Trade Plans - metal.it
What are JACS’s earnings expectationsConsistent Triple Digit Profits - classian.co.kr
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, - openPR.com
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux - Barchart.com
Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc - TipRanks
Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target - TipRanks
Janux Therapeutics Earns Buy Rating Amid Promising Pipeline and Strong Financial Position. - AInvest
Janux Therapeutics First Half 2025 Earnings: US$0.93 loss per share (vs US$0.41 loss in 1H 2024) - Yahoo Finance
RSI Crosses Above 30 for Janux Therapeutics Inc. — Reversal in SightTarget Return Focused Trade Insights Shared - metal.it
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating, Cuts Target Price to $59 - 富途牛牛
Janux Therapeutics (NASDAQ:JANX) Hits New 52-Week Low on Disappointing Earnings - Defense World
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position - TipRanks
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $59 to $100 - 富途牛牛
Janux Therapeutics 2024 Q3 Earnings Widening Losses Amidst Revenue Decline - AInvest
Janux Therapeutics stock hits 52-week low at 22.25 USD - Investing.com
Janux Therapeutics stock hits 52-week low at 22.25 USD By Investing.com - Investing.com Nigeria
Janux Therapeutics 2024 Q3 Earnings Deepening Losses Amid Pipeline Progress - AInvest
Janux (JANX) R&D Soars Revenue Misses - AOL.com
Janux Therapeutics Reports Q2 2025 Financial Results - TipRanks
Janux Therapeutics Inc. Receives Buy Rating for Promising Pipeline and Financial Stability - AInvest
Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating - TipRanks
Optimistic Buy Rating for Janux Therapeutics Inc. Driven by Promising R&D, Strong Cash Position, and Strategic Expansion - TipRanks
Janux Therapeutics reports Q2 EPS (55c), consensus (47c) - TipRanks
Janux Therapeutics Reports Q2 FY25 Financial Results, $996mln Cash, Milestone Payment from Merck. - AInvest
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Janux Therapeutics Inc Stock (JANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
May 01 '25 |
Sale |
32.03 |
3,333 |
106,745 |
82,139 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):